GlassScriptPhysician profile
Mahendra C Patel
NPI 1194739342
$2,309.46
in general payments reported to CMS, 2019-2025
21 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $106 · 2021: $201 · 2022: $349 · 2023: $521 · 2024: $338 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $295.24 | 2022-2025 | Advate, Adynovate, Hyqvia |
| Novartis Pharmaceuticals Corporation | $285.32 | 2019-2023 | |
| Mckesson Specialty Care Distribution, LLC | $232.05 | 2019 | |
| Octapharma USA, INC. | $210.90 | 2022-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Rigel Pharmaceuticals, INC. | $198.92 | 2020-2023 | Tavalisse, Rezlidhia |
| Genetix Biotherapeutics INC | $185.26 | 2023 | |
| Csl Behring | $175.94 | 2019-2023 | Idelvion |
| Pfizer INC. | $159.57 | 2022-2025 | |
| Pharming Healthcare, INC. | $113.76 | 2023-2025 | Ruconest |
| Novo Nordisk INC | $85.68 | 2019-2025 | Esperoct |
| US Oncology Corporate, INC. | $77.51 | 2021-2024 | |
| Global Blood Therapeutics, INC. | $73.98 | 2022 | |
| Genzyme Corporation | $67.88 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $30.17 | 2024 | Dupixent |
| Catalyst Pharmaceuticals, INC. | $20.28 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $18.61 | 2020 | |
| Apo-Pharma USA, INC. | $16.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.59 | 2022 | |
| Grifols USA, LLC | $16.01 | 2024 | Gamunex-C |
| Fortovia Therapeutics, INC. | $15.73 | 2019 | |
| Glaxosmithkline, LLC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.